Member Info for KUMS

force & time to take advantage of under 2p.

of under 10p days! OXB is gathering force. One to stay put & it has delivered for those getting in a 3p in Oct last year. And not getting excited when it drops is really paying off. Ater all, red days are there for all the shares! Becoming a mulltibaggar!

Paid. Nice. Have good evening all & weekend.

Now.

Hope this does OXB. I have been in & out so many time before but this now looks good to take off. Some OXB profit has gone in here. Hope this is a multibaggar from here!

paid.

that is!

buy yesterday says it all! Then we had several big buys & it has continued today. Volumes traded so far today::4,319,998

buys coming up. Towards 10p idc.

be increasing as we grt closer to FDA hearing date. Further, there is a lot written about CTL109 by different people,charities, insttutions, doctors all over the world that this is going to change lives. We could see under 10p as a big big bargain. DYOR!

was big buy this morning attracting more buyers.

up 8.31%

now.

Position will once again be taken and with some red days, overall this should head past 9p & then 10p before FDA decision date.

Oxford BioMedica launches its new beautiful website. Please take a look around. http://Www.oxfordbiomedica.co.uk @OxfordBioMedica

move up to 28/30p!

also known as CTL019. If the F.D.A. accepts the recommendation, which is likely, the treatment will be the first gene therapy ever to reach the market. Others are expected: Researchers and drug companies have been engaged in intense competition for decades to reach this milestone. Novartis is now poised to be the first. NY Times.

here before FDA decision expected late Sept/Oct this year. At 5p, many investors took advantage of sp as interest was going to increase before FDA Advisory decision which we saw this month. SP more then doubled! Same will happen from here onwards to FDA decision date whether to accept/reject the recommendation. SP should be north of 11p by then & those buying now could decided to sell/top slice etc. I took advantage of sp on Monday with open arms. Decision, Decision!

UP!

on CNBC this morning! CTL019 should be approved Oct in USA. It is about to enter next growth phase. Pricing structure after this. Will be selling in 2018 onwards.